X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 22, 2020

SARS-CoV-2 Vaccines – Primary Packaging Challenges

Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
Page McAndrew

Page McAndrew PhD.

Director, Scientific Communications

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts

    March 13, 2020

    Multiple Benefits of Elastomeric Closures with FluroTec® Barrier Film

    Gabrielle Gehron

    Gabrielle Gehron

    Associate Technical Account Specialist, TCS

    Fluoropolymer

    December 06, 2019

    Advantages of Fluoropolymer-Laminated Components

    Candice Sun

    Candice Sun

    Specialist, Scientific Affairs, CN

    Blue West logo with Diamond

    June 27, 2013

    High-Quality Components Help Reduce Extractables in PFS Systems

    West Pharma

    Whitney Winters

    Director, Sales, Emerging Biologics